Despite plenty of studies investigating the effectiveness of targeted therapy, there were still no suitable biomarkers to predict the anti‐tumor activity of anti‐EGFR or anti‐VEGF/VEGFR agents.34, 35. This evidence concerns the gene EGFR and neoplasm.